Strides Pharma Science Limited — Updates, 29-07-2025: Press Release

Strides Pharma delivered a strong Q1FY26. Revenue grew 6.2% YoY to ₹1,119.7 Cr, with EBITDA up 14.8% to ₹218.1 Cr. Operational PAT surged 80.6% to ₹114.0 Cr, driven by improved margins and disciplined execution. US revenue grew 7.0% to $71m, with the company progressing on its $400m generics revenue target by FY27-28 via reactivating dormant ANDAs and exploring new segments. Other regulated markets and growth markets also saw increases, while access markets faced headwinds from reduced donor funding. Net debt reduced by ₹26.4 Cr, funded internally, demonstrating strong financial discipline. The company plans to enhance R&D for long-term growth.